Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion

•Donor lymphocyte infusion is one of most important options in the treatment of relapsed hematological malignancies after hematopoietic stem cell transplantation.•The effect of donor lymphocyte infusion depends on the balance between graft-versus-leukemia and acute graft-versus-host disease.•Ruxolitinib can regulate immune reaction to control the effect of acute graft-versus-host disease.